COGNITION THERAPEUTICS INC Stock Price, News & Analysis

Cognition Therapeutics (NASDAQ: CGTX) reported its Q1 2025 financial results and provided key business updates. The company has requested an end-of-Phase 2 meeting with the FDA to review results from the SHINE study in Alzheimer's disease. Their Phase 2 'SHIMMER' study results in dementia with Lewy bodies (DLB) were accepted for presentation at AAIC 2025.

Financial highlights include: cash position of $16.4 million as of March 31, 2025, with $47.0 million in remaining NIH grant funds. Q1 2025 saw R&D expenses of $10.8 million and G&A expenses of $3.0 million. Net loss was $8.5 million ($0.14 per share), improved from $9.2 million ($0.27 per share) in Q1 2024. The company expects current cash to fund operations into Q4 2025.

Cognition Therapeutics (NASDAQ: CGTX) presented biomarker results from their Phase 2 SHINE study of zervimesine (CT1812) in mild-to-moderate Alzheimer's disease at the AD/PD™ 2025 Conference. The study revealed that patients treated with zervimesine for six months showed reductions in key plasma biomarkers associated with Alzheimer's disease processes compared to placebo.

Notably, a prespecified subgroup of patients with lower initial p-Tau217 levels demonstrated more pronounced reductions in important biomarkers, including:

• Significant decreases in glial fibrillary acidic protein (GFAP), linked to neuroinflammation
• Reduced levels of neurofilament light (NfL), associated with neurodegeneration
• Lower amounts of amyloid beta (Aβ) and tau species (p-Tau217)

The findings align with the cognitive benefits observed in the study population, particularly in the low-p-Tau217 subgroup, supporting zervimesine's mechanism of action in impacting disease progression.

Cognition Therapeutics (NASDAQ: CGTX) will present biomarker results from their Phase 2 SHINE study of zervimesine (CT1812) in mild-to-moderate Alzheimer's disease at the AD/PD™ 2025 Conference in Vienna. The presentation, scheduled for April 1-5, 2025, will focus on analyzing key blood sample biomarkers including neurofilament light chain, glial fibrillary acidic protein, amyloid beta, and tau species.

Dr. Mary Hamby, VP of research, will deliver a podium presentation examining the drug's impact on disease biology by comparing biomarker changes between zervimesine and placebo groups. The presentation will complement previously reported positive cognitive and functional findings to provide a comprehensive understanding of the drug's effectiveness.

Additional poster presentations will cover CSF proteomic biomarker analysis, correlation of CSF proteins with cognitive outcomes, and molecular correlates with CT1812 treatment-related changes in NfL CSF levels.

Cognition Therapeutics (NASDAQ: CGTX) has reported its financial results for Q4 and full-year 2024, highlighting significant progress in its neurodegenerative disorder treatments. The company's lead candidate, zervimesine (CT1812), showed promising results in two Phase 2 studies:

The SHIMMER study in Dementia with Lewy Bodies (DLB) demonstrated up to 91% slowing compared to placebo across behavioral, functional, cognitive, and movement measures. The SHINE study in Alzheimer's disease revealed near-total preservation of cognition in patients with lower p-tau217 levels.

Financial highlights include:

• Cash position of $25.0 million as of December 31, 2024
• $50.0 million in remaining NIA grant funds
• R&D expenses increased to $41.7 million from $37.2 million in 2023
• Net loss of $34.0 million ($0.86 per share)

The company plans to advance zervimesine into Phase 3 trials for both DLB and Alzheimer's, with FDA meetings expected in early Q2 2025. Cash runway extends into Q4 2025.

Cognition Therapeutics (Nasdaq: CGTX), a clinical stage company focused on neurodegenerative disorders treatment, has announced it will release its Q4 and full-year 2024 financial results on Thursday, March 20, 2025, before market open. The company will host a conference call at 8:00 a.m. ET on the same day, during which management will review financial and operating results and provide a business update.

Cognition Therapeutics (CGTX) has received a notification from Nasdaq regarding its transfer from The Nasdaq Global Market to The Nasdaq Capital Market, effective March 14, 2025. This follows the company's failure to maintain a minimum bid price of $1.00 per share over 30 consecutive business days, as initially notified on September 12, 2024.

The company has been granted an additional 180 calendar days until September 8, 2025, to regain compliance by achieving a closing bid price of at least $1.00 per share for 10 consecutive business days. If compliance is not achieved naturally, CGTX may seek stockholder approval for a reverse stock split, which would need to be implemented at least 10 business days before the compliance period ends.

Cognition Therapeutics (NASDAQ: CGTX), a clinical stage company focused on neurodegenerative disorders, has announced that President and CEO Lisa Ricciardi will deliver a live presentation at the Life Sciences Virtual Investor Conference on March 13, 2025, at 9:30 a.m. ET.

The presentation will outline the company's 2025 plans for advancing zervimesine (CT1812) in Alzheimer's disease and dementia with Lewy bodies, following positive Phase 2 data readouts. The interactive online event will feature real-time Q&A with the management team.

Investors unable to attend the live event can access an archived webcast through Cognition's Investor Relations webpage. Pre-registration is recommended for interested participants at www.virtualinvestorconferences.com.

Cognition Therapeutics (Nasdaq: CGTX) has published research in Nature Scientific Reports demonstrating the potential of their drug candidate zervimesine (CT1812) in treating dry age-related macular degeneration (dry AMD).

The research comprised multiple studies, including analysis of cerebrospinal fluid from Alzheimer's disease clinical trials and collaborative in vitro research with the University of Southampton. The studies revealed that zervimesine treatment altered proteins and pathways associated with geographic atrophy and macular degeneration.

Laboratory tests showed that zervimesine could rescue impaired cellular processes in retinal pigment epithelial (RPE) cells, which are important for breaking down photoreceptor debris and maintaining sight. While the results support zervimesine's potential in treating dry AMD, the company will currently focus its financial resources on Alzheimer's disease and dementia with Lewy bodies.